6-styryl-naphthalene-2-carbonitrile | 220299-35-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 6-styryl-naphthalene-2-carbonitrile
• 英文别名: (E)-6-[2-(Phenyl)ethenyl]-2-naphthalenecarbonitrile；6-[(E)-2-phenylethenyl]naphthalene-2-carbonitrile
• CAS: 220299-35-4
• 化学式: C₁₉H₁₃N
• 分子量: 255.319
• InChiKey: NTVNJDUEESOJBK-VOTSOKGWSA-N

物化性质

• 沸点：
  452.7±20.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-styryl-naphthalene-2-carbonitrile 在 lithium hexamethyldisilazane 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 6-Styryl-naphthalene-2-carboxamidine
  参考文献：
  名称：

  Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties

  摘要：

  A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.026
• 作为产物：
  描述：

  6-cyano-naphthalene-2-carboxylic acid methyl ester 在 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 、 calcium chloride 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 生成 6-styryl-naphthalene-2-carbonitrile
  参考文献：
  名称：

  Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties

  摘要：

  A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.026

文献信息

• Urokinase inhibitors
  申请人：Abbott Laboratories

  公开号：US06258822B1

  公开（公告）日：2001-07-10

  Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.

  具有该公式的化合物是尿激酶的抑制剂，对于尿激酶在其中发挥作用的疾病的治疗是有用的。还公开了抑制尿激酶的组合物和在哺乳动物中抑制尿激酶的方法。
• Ukokinase inhibitors
  申请人：Abbott Laboratories

  公开号：US06284796B1

  公开（公告）日：2001-09-04

  Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.

  具有该化学式的化合物是尿激酶的抑制剂，对于尿激酶在某些疾病治疗中起作用是有用的。还公开了抑制尿激酶的组合物和在哺乳动物中抑制尿激酶的方法。
• Novel amidrazone derivatives: Design, synthesis and activity evaluation
  作者：Hua Zhou、Zhi Sen Wang、Xin Hua Liu、Fei Hu Chen

  DOI：10.1016/j.bmc.2018.04.042

  日期：2018.7

  A series of new 6-styryl-naphthalene-2-amidrazone derivatives were synthesized and evaluated as potential ASIC1a inhibitors. Among them, compound 5e showed the most activity to inhibit [Ca2+]i. elevation in acid-induced articular chondrocytes. Together with the important role of ASIC1a in the pathogenesis of tissue acidification diseases including rheumatoid arthritis, these results might provide a

  合成了一系列新的6-苯乙烯基萘-2-氨基dra酮衍生物，并将其评估为潜在的ASIC1a抑制剂。其中，化合物5e显示出抑制[Ca 2+] i的最大活性。酸诱导的关节软骨细胞升高。连同ASIC1a在包括类风湿性关节炎在内的组织酸化疾病的发病机理中的重要作用，这些结果可能为开发针对组织酸化疾病的药物提供有意义的提示或启发。
• US6258822B1
  申请人：——

  公开号：US6258822B1

  公开（公告）日：2001-07-10
• US6284796B1
  申请人：——

  公开号：US6284796B1

  公开（公告）日：2001-09-04